FDA Advisory Committee Unanimously Recommends Approval Of FDA’s SIVEXTRO (Tedizolid Phosphate) As Treatment For Serious Skin Infections
4/1/2014 8:18:49 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today that the U.S. Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) voted to recommend approval of Cubist’s investigational antibiotic SIVEXTRO™ (tedizolid phosphate). In the unanimous 14 - 0 decision, the AIDAC found that substantial evidence of the safety and effectiveness of SIVEXTRO for the treatment of acute bacterial skin and skin structure infections (ABSSSI) was provided.
Help employers find you! Check out all the jobs and post your resume.
comments powered by